These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23454131)

  • 21. New classes of PDE7 inhibitors identified by a fission yeast-based HTS.
    Alaamery MA; Wyman AR; Ivey FD; Allain C; Demirbas D; Wang L; Ceyhan O; Hoffman CS
    J Biomol Screen; 2010 Apr; 15(4):359-67. PubMed ID: 20228279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders.
    Safavi M; Baeeri M; Abdollahi M
    Expert Opin Drug Discov; 2013 Jun; 8(6):733-51. PubMed ID: 23570245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.
    Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
    J Med Chem; 2000 Dec; 43(26):5037-43. PubMed ID: 11150175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
    Chłoń-Rzepa G; Jankowska A; Ślusarczyk M; Świerczek A; Pociecha K; Wyska E; Bucki A; Gawalska A; Kołaczkowski M; Pawłowski M
    Eur J Med Chem; 2018 Feb; 146():381-394. PubMed ID: 29407965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
    Redondo M; Zarruk JG; Ceballos P; Pérez DI; Pérez C; Perez-Castillo A; Moro MA; Brea J; Val C; Cadavid MI; Loza MI; Campillo NE; Martínez A; Gil C
    Eur J Med Chem; 2012 Jan; 47(1):175-85. PubMed ID: 22100138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QSAR study of phosphodiesterase inhibitory activity of imidazo[2,1-b]-quinazolines: active site analysis.
    Prabhakar YS
    Drug Des Deliv; 1989 Dec; 5(2):81-91. PubMed ID: 2577989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cloning, stable expression of human phosphodiesterase 7A and development of an assay for screening of PDE7 selective inhibitors.
    Malik R; Bora RS; Gupta D; Sharma P; Arya R; Chaudhary S; Saini KS
    Appl Microbiol Biotechnol; 2008 Jan; 77(5):1167-73. PubMed ID: 17952431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases.
    Martinez A; Gil C
    Expert Opin Ther Pat; 2014 Dec; 24(12):1311-21. PubMed ID: 25284693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.
    Humphrey JM; Movsesian M; Am Ende CW; Becker SL; Chappie TA; Jenkinson S; Liras JL; Liras S; Orozco C; Pandit J; Vajdos FF; Vandeput F; Yang E; Menniti FS
    J Med Chem; 2018 May; 61(10):4635-4640. PubMed ID: 29718668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
    Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
    Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorine-containing 6,7-dialkoxybiaryl-based inhibitors for phosphodiesterase 10 A: synthesis and in vitro evaluation of inhibitory potency, selectivity, and metabolism.
    Schwan G; Barbar Asskar G; Höfgen N; Kubicova L; Funke U; Egerland U; Zahn M; Nieber K; Scheunemann M; Sträter N; Brust P; Briel D
    ChemMedChem; 2014 Jul; 9(7):1476-87. PubMed ID: 24729456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
    Ručilová V; Świerczek A; Vanda D; Funk P; Lemrová B; Gawalska A; Bucki A; Nowak B; Zadrożna M; Pociecha K; Soural M; Wyska E; Pawłowski M; Chłoń-Rzepa G; Zajdel P
    Eur J Med Chem; 2021 Jan; 209():112854. PubMed ID: 33022582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
    Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-(beta-Arylethylamino)- and 4-(beta-arylethylamino)quinazolines as phosphodiesterase inhibitors.
    Millen J; Riley TN; Waters IW; Hamrick ME
    J Med Chem; 1985 Jan; 28(1):12-7. PubMed ID: 3965705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.